|
| 多替拉韦联合拉米夫定简化方案
治疗初治HIV感染者真实世界研究 |
| Dolutegravir plus lamivudine in antiretroviral-naive adults with HIV infection |
| |
| DOI：10.3969/j.issn.1007-8134.2022.06.005 |
| 中文关键词: HIV AIDS 多替拉韦 拉米夫定 二联简化方案 真实世界 临床疗效 安全性研究 不良反应 优化治疗 |
| 英文关键词: HIV AIDS dolutegravir lamivudine real-world study viral suppression rate CD4+ T cell count inflammatory factors |
| 基金项目:珠海市科技局面上项目（ZH2202200017HJL）；中山大学热带病防治研究教育部部重点实验室（2018kfkt） |
|
| 摘要点击次数: 146 |
| 全文下载次数: 0 |
| 中文摘要: |
| [摘要] 目的 初步观察多替拉韦联合拉米夫定简化方案治疗初治HIV感染者的临床疗效。方法 采用前瞻性观察研究方法，筛选我院门诊确诊的HIV/AIDS患者，接受多替拉韦联合拉米夫定简化方案治疗，观察治疗期间CD4+ T细胞计数、CD4/CD48比值、HIV载量及炎症因子的变化情况。结果 27例患者在治疗12周时病毒抑制率为62.96%，24周和48周时分别为92.31%和100%；CD4+ T细胞计数在治疗12周时上升为（340.53±235.39）个/μl，24周时上升为（430.26±291.71）个/μl（P均＜0.05）；治疗前44.44%的患者合并机会性感染，其治疗前升高的炎症因子在治疗后均逐渐下降。结论 多替拉韦联合拉米夫定简化治疗初治的HIV/AIDS患者可以获得较高的病毒抑制率，尤其可以作为晚期患者的优化方案。 |
| 英文摘要: |
| [Abstract] Objective This study aimed to evaluate the efficacy of a two-drug regimen comprising dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV infection in HAART-naive adults. Methods?We performed a prospective real world study of HIV-infected patients on dolutegravir plus lamivudine regimen treatment and analysed their change of plasma HIVRNA level, CD4+ T cell count, CD4/CD8 ratio and inflammatory factors. Results?Twenty-seven antiretroviral-naive patients were enrolled. The viral suppression rate was 62.96% at week 12, 92.3% at week 24 and 100% at week 48. CD4+ T cell count was (340.53±235.39) /μl at week 12 (P＜0.05)and (430.26±291.71) /μl at week 24 (P＜0.05). Besides, before treatment, 44.44% patients had opportunistic infectionand increased inflammatory factors which decreased after treatment. Conclusions?The two-drug regimen(Dolutegravir plus lamivudine) achieved a high viral suppression rate in antiretroviral -naive adults, especially for advanced patients. |
|
HTML
查看全文
下载PDF阅读器 |
| 关闭 |